Craig Lindsley
-
New drug candidates targeting blood clots developed through computer-aided drug design
Using computer-aided drug design, the labs of Heidi Hamm, Jens Meiler, and Craig Lindsley generated a novel series of biologically active compounds that can serve as a basis for anti–blood clot preventative drugs. Read MoreJun. 6, 2024
-
Lab-to-Table Conversation: Beyond Addiction: Therapeutic Developments and Societal Impact, on Jan. 24
Join the next Lab-to-Table conversation, “Beyond Addiction: Therapeutic Developments and Societal Impact” on Jan. 24 at 11:30 a.m. CT. Read MoreJan. 11, 2024
-
Potential schizophrenia treatment, discovered at Vanderbilt and being developed by Neumora Therapeutics, entering Phase 1 clinical trial
A potential schizophrenia treatment discovered through the Warren Center for Neuroscience Drug Discovery has been cleared by the U.S. Food and Drug Administration for use in phase 1 clinical trials—the third WCNDD therapeutic to reach that benchmark. “Vanderbilt is proud that a discovery by our researchers at the Warren Center… Read MoreDec. 4, 2023
-
Vanderbilt scientists make headway in drug development to cure pulmonary arterial hypertension
Research by David Merryman and Craig Lindsley has resulted in the development of VU6047534, a new drug that treats pulmonary arterial hypertension—a type of high blood pressure that affects arteries in the lungs and in the heart—without serious neurological side effects. The article, “Development of a Peripherally Restricted… Read MoreSep. 13, 2023
-
Lindsley named 2022 fellow of American Society for Pharmacology and Experimental Therapeutics
Craig W. Lindsley, University Distinguished Professor of Pharmacology, Biochemistry and Chemistry, who holds the William K. Warren, Jr. Chair in Medicine, was recently announced as a 2022 fellow of the American Society for Pharmacology and Experimental Therapeutics for his demonstrated excellence and… Read MoreNov. 30, 2022
-
Vanderbilt, international collaborators discover treatment to slow neurodegenerative diseases
Craig Lindsley, the William K. Warren, Jr. Professor of Medicine and director of Vanderbilt University’s Warren Center for Neuroscience Drug Discovery, and Jeffrey Conn, founding director of the WCNDD and professor emeritus of pharmacology, have contributed seminal work… Read MoreNov. 15, 2022
-
Prothena and Warren Center for Neuroscience Drug Discovery collaborate on new Alzheimer’s disease therapeutics
Prothena and the Warren Center for Neuroscience Drug Discovery have entered into a collaborative research agreement to develop new small molecule therapeutics for the treatment of Alzheimer’s disease in individuals with Down syndrome. Down syndrome is a condition in which a person’s having… Read MoreApr. 22, 2022
-
WCNDD-developed Parkinson’s drug to enter next phase of clinical trial
A drug aimed at improving the lives of patients living with Parkinson’s disease will go to the next phase of clinical trials, thanks to a $13.5 million investment raised by Nashville’s Appello Pharmaceuticals. The clinical-stage pharmaceutical company that focuses on nervous system disorders announced Tuesday that its lead drug,… Read MoreApr. 4, 2022
-
Vanderbilt extends its longest ongoing drug discovery agreement with pharmaceutical company through 2023
Vanderbilt has extended its longest ongoing drug discovery agreement with Osaka, Japan-based Ono Pharmaceutical Co., Ltd., a research and development-oriented pharmaceutical company that is committed to creating innovative medicines in specific areas, through November 2023. The initial agreement was signed in November… Read MoreDec. 22, 2021
-
Deciphering the Circuits in Neuroscience Research
Around 500 million people around the world are affected by poor mental health including disorders such as depression, schizophrenia, bipolar disease and dementia with a significant impact on quality of life as well as associated social and economic consequences.1 Boehringer Ingelheim is dedicated to redefining the management of mental health. Read MoreDec. 7, 2021